Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment : results from the CRITICS trial. / Slagter, Astrid E.; Vollebergh, Marieke A.; Caspers, Irene A. et al.

I: Gastric Cancer, Bind 25, Nr. 2, 03.2022, s. 401-410.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Slagter, AE, Vollebergh, MA, Caspers, IA, van Sandick, JW, Sikorska, K, Lind, P, Nordsmark, M, Putter, H, Braak, JPBM, Meershoek-Klein Kranenbarg, E, van de Velde, CJH, Jansen, EPM, Cats, A, van Laarhoven, HWM, van Grieken, NCT & Verheij, M 2022, 'Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial', Gastric Cancer, bind 25, nr. 2, s. 401-410. https://doi.org/10.1007/s10120-021-01258-6

APA

Slagter, A. E., Vollebergh, M. A., Caspers, I. A., van Sandick, J. W., Sikorska, K., Lind, P., Nordsmark, M., Putter, H., Braak, J. P. B. M., Meershoek-Klein Kranenbarg, E., van de Velde, C. J. H., Jansen, E. P. M., Cats, A., van Laarhoven, H. W. M., van Grieken, N. C. T., & Verheij, M. (2022). Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial. Gastric Cancer, 25(2), 401-410. https://doi.org/10.1007/s10120-021-01258-6

CBE

Slagter AE, Vollebergh MA, Caspers IA, van Sandick JW, Sikorska K, Lind P, Nordsmark M, Putter H, Braak JPBM, Meershoek-Klein Kranenbarg E, et al. 2022. Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial. Gastric Cancer. 25(2):401-410. https://doi.org/10.1007/s10120-021-01258-6

MLA

Vancouver

Slagter AE, Vollebergh MA, Caspers IA, van Sandick JW, Sikorska K, Lind P et al. Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial. Gastric Cancer. 2022 mar.;25(2):401-410. doi: 10.1007/s10120-021-01258-6

Author

Slagter, Astrid E. ; Vollebergh, Marieke A. ; Caspers, Irene A. et al. / Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment : results from the CRITICS trial. I: Gastric Cancer. 2022 ; Bind 25, Nr. 2. s. 401-410.

Bibtex

@article{c58722c293684ce5ba72b2519a345bd1,
title = "Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial",
abstract = "Aim: To evaluate the prognostic value of tumor markers in a European cohort of patients with resectable gastric cancer. Methods: We performed a post hoc analysis of the CRITICS trial, in which 788 patients received perioperative therapy. Association between survival and pretreatment CEA, CA 19-9, alkaline phosphatase, neutrophils, hemoglobin and lactate dehydrogenase were explored in uni- and multivariable Cox regression analyses. Likelihoods to receive potentially curative surgery were investigated for patients without elevated tumor markers versus one of the tumor markers elevated versus both tumor markers elevated. The association between tumor markers and the presence of circulating tumor DNA (ctDNA) was explored in 50 patients with available ctDNA data. Results: In multivariable analysis, in which we corrected for allocated treatment and other baseline characteristics, elevated pretreatment CEA (HR 1.43; 95% CI 1.11–1.85, p < 0.001) and CA 19-9 (HR 1.79; 95% CI 1.42–2.25, p < 0.001) were associated with worse OS. Likelihoods to receive potentially curative surgery were 86%, 77% and 60% for patients without elevated tumor marker versus either elevated CEA or CA 19-9 versus both elevated, respectively (p < 0.001). Although both preoperative presence of ctDNA and tumor markers were prognostic for survival, no association was found between these two parameters. Conclusion: CEA and CA 19-9 were independent prognostic factors for survival in a large cohort of European patients with resectable gastric cancer. No relationship was found between tumor markers and ctDNA. These factors could potentially guide treatment choices and should be included in future trials to determine their definitive position. Trial registration: ClinicalTrial.gov identifier: NCT00407186. EudraCT number: 2006-00413032.",
keywords = "CA 19-9, CEA, ctDNA, Resectable gastric cancer, Tumor markers",
author = "Slagter, {Astrid E.} and Vollebergh, {Marieke A.} and Caspers, {Irene A.} and {van Sandick}, {Johanna W.} and Karolina Sikorska and Pehr Lind and Marianne Nordsmark and Hein Putter and Braak, {Jeffrey P.B.M.} and {Meershoek-Klein Kranenbarg}, Elma and {van de Velde}, {Cornelis J.H.} and Jansen, {Edwin P.M.} and Annemieke Cats and {van Laarhoven}, {Hanneke W.M.} and {van Grieken}, {Nicole C.T.} and Marcel Verheij",
note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2022",
month = mar,
doi = "10.1007/s10120-021-01258-6",
language = "English",
volume = "25",
pages = "401--410",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment

T2 - results from the CRITICS trial

AU - Slagter, Astrid E.

AU - Vollebergh, Marieke A.

AU - Caspers, Irene A.

AU - van Sandick, Johanna W.

AU - Sikorska, Karolina

AU - Lind, Pehr

AU - Nordsmark, Marianne

AU - Putter, Hein

AU - Braak, Jeffrey P.B.M.

AU - Meershoek-Klein Kranenbarg, Elma

AU - van de Velde, Cornelis J.H.

AU - Jansen, Edwin P.M.

AU - Cats, Annemieke

AU - van Laarhoven, Hanneke W.M.

AU - van Grieken, Nicole C.T.

AU - Verheij, Marcel

N1 - Publisher Copyright: © 2021, The Author(s).

PY - 2022/3

Y1 - 2022/3

N2 - Aim: To evaluate the prognostic value of tumor markers in a European cohort of patients with resectable gastric cancer. Methods: We performed a post hoc analysis of the CRITICS trial, in which 788 patients received perioperative therapy. Association between survival and pretreatment CEA, CA 19-9, alkaline phosphatase, neutrophils, hemoglobin and lactate dehydrogenase were explored in uni- and multivariable Cox regression analyses. Likelihoods to receive potentially curative surgery were investigated for patients without elevated tumor markers versus one of the tumor markers elevated versus both tumor markers elevated. The association between tumor markers and the presence of circulating tumor DNA (ctDNA) was explored in 50 patients with available ctDNA data. Results: In multivariable analysis, in which we corrected for allocated treatment and other baseline characteristics, elevated pretreatment CEA (HR 1.43; 95% CI 1.11–1.85, p < 0.001) and CA 19-9 (HR 1.79; 95% CI 1.42–2.25, p < 0.001) were associated with worse OS. Likelihoods to receive potentially curative surgery were 86%, 77% and 60% for patients without elevated tumor marker versus either elevated CEA or CA 19-9 versus both elevated, respectively (p < 0.001). Although both preoperative presence of ctDNA and tumor markers were prognostic for survival, no association was found between these two parameters. Conclusion: CEA and CA 19-9 were independent prognostic factors for survival in a large cohort of European patients with resectable gastric cancer. No relationship was found between tumor markers and ctDNA. These factors could potentially guide treatment choices and should be included in future trials to determine their definitive position. Trial registration: ClinicalTrial.gov identifier: NCT00407186. EudraCT number: 2006-00413032.

AB - Aim: To evaluate the prognostic value of tumor markers in a European cohort of patients with resectable gastric cancer. Methods: We performed a post hoc analysis of the CRITICS trial, in which 788 patients received perioperative therapy. Association between survival and pretreatment CEA, CA 19-9, alkaline phosphatase, neutrophils, hemoglobin and lactate dehydrogenase were explored in uni- and multivariable Cox regression analyses. Likelihoods to receive potentially curative surgery were investigated for patients without elevated tumor markers versus one of the tumor markers elevated versus both tumor markers elevated. The association between tumor markers and the presence of circulating tumor DNA (ctDNA) was explored in 50 patients with available ctDNA data. Results: In multivariable analysis, in which we corrected for allocated treatment and other baseline characteristics, elevated pretreatment CEA (HR 1.43; 95% CI 1.11–1.85, p < 0.001) and CA 19-9 (HR 1.79; 95% CI 1.42–2.25, p < 0.001) were associated with worse OS. Likelihoods to receive potentially curative surgery were 86%, 77% and 60% for patients without elevated tumor marker versus either elevated CEA or CA 19-9 versus both elevated, respectively (p < 0.001). Although both preoperative presence of ctDNA and tumor markers were prognostic for survival, no association was found between these two parameters. Conclusion: CEA and CA 19-9 were independent prognostic factors for survival in a large cohort of European patients with resectable gastric cancer. No relationship was found between tumor markers and ctDNA. These factors could potentially guide treatment choices and should be included in future trials to determine their definitive position. Trial registration: ClinicalTrial.gov identifier: NCT00407186. EudraCT number: 2006-00413032.

KW - CA 19-9

KW - CEA

KW - ctDNA

KW - Resectable gastric cancer

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=85118406843&partnerID=8YFLogxK

U2 - 10.1007/s10120-021-01258-6

DO - 10.1007/s10120-021-01258-6

M3 - Journal article

C2 - 34714423

AN - SCOPUS:85118406843

VL - 25

SP - 401

EP - 410

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 2

ER -